The Board of Directors inter-alia has approved and taken on record Un-Audited Standalone and Consolidated Financial Results for the half year ended 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts less than Nifty Microcap 250 and 4.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Trident Lifeline's board approved unaudited H1 FY26 results (ended Sept 30, 2025) along with a clean limited review report from A Bafna & Associates. On a standalone basis, revenue from operations rose about 52% YoY to Rs 4,625.86 lakhs and net profit grew roughly 31% to Rs 841.71 lakhs, translating to EPS of Rs 7.26 (vs Rs 5.57). On a consolidated basis, including five subsidiaries, revenue jumped about 82% to Rs 5,335.68 lakhs and PAT after minority interest climbed about 49% to Rs 801.13 lakhs. However, EBITDA margin slipped to around 27% from about 30% a year ago as material and employee costs outpaced revenue. Operating cash flow turned sharply negative at about Rs 824 lakhs standalone and Rs 938 lakhs consolidated, mainly due to a big jump in trade receivables and inventory.
Strong revenue and profit growth, helped by recent subsidiary additions, is a positive for shareholders, but the falling margin and negative operating cash flow point to working-capital stress that could weigh on sentiment if not corrected.